ClinicalTrials.gg
Not yet recruitingNCT07382661Updated Feb 4, 2026

Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin

A Phase 1 interventional study of DW4421 and DW4421-1 in Healthy Adult Volunteers, sponsored by Daewon Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

Drug-Drug Interaction between DW4421 and Amoxicillin/Clarithromycin

02

Conditions studied

  • Healthy Adult Volunteers
03

In context

Lead sponsor

Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.
  • Subjects weighing between 50 kg and 90 kg with between 18 and 27 kg/m2 (inclusive) at screening visit.

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Sequence 1

    A-B-C (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

  • Experimental
    Sequence 2

    A-C-B (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

  • Experimental
    Sequence 3

    B-A-B (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

  • Experimental
    Sequence 4

    B-C-A (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

  • Experimental
    Sequence 5

    C-A-B (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

  • Experimental
    Sequence 6

    C-B-A (A: DW4421 1T bid; B: DW4421-1 2C bid + DW4421-2 1T bid; C: DW4421 1T bid + DW4421-1 2C bid + DW4421-2 1T bid)

    Drug: DW4421 · Drug: DW4421-1 · Drug: DW4421-2

Interventions

  • DrugDW4421

    1 tablet will be orally administered

  • DrugDW4421-1

    2 capsules will be orally administered

  • DrugDW4421-2

    1 tablet will be orally administered

06

What researchers measure

Primary outcomes

  1. Cmax,ss: Maximum concentration of DW4421, DW4421-1 and DW4421-2 at steady state

    Time frame: Up to day 6 or day 7

  2. AUCτ,ss: Area under the drug concentration-time curve of DW4421, DW4421-1, DW4421-2 within a dosing interval at steady state

    Time frame: Up to day 6 or day 7

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for May 2026, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 3, 2026
StartEst.
Feb 2026
Primary completionEst.
May 2026
CompletionEst.
Oct 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07382661
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Feb 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DW4421

Start the discussion